Recent Price Movement and Market Context
The stock of Piramal Pharma has been trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a persistent bearish trend. Over the last six days, the stock has recorded a cumulative return of -7.86%, underperforming its Pharmaceuticals & Biotechnology sector by approximately 1.52% on the day of the new low.
In contrast, the broader market index, Sensex, opened flat but later declined by 216.22 points, or 0.32%, closing at 84,391.27. Despite this dip, Sensex remains close to its 52-week high of 86,159.02, trading just 2.09% below that peak and maintaining a bullish stance above its 50-day and 200-day moving averages.
Long-Term Performance and Valuation Metrics
Over the past year, Piramal Pharma’s stock has recorded a negative return of 34.28%, a stark contrast to the Sensex’s positive 3.53% return during the same period. The stock’s 52-week high was Rs.273.20, indicating a significant decline from that level to the current low of Rs.170.15.
From a valuation perspective, the company’s Return on Capital Employed (ROCE) stands at 2.7%, with an Enterprise Value to Capital Employed ratio of 2.2. These figures suggest a fair valuation relative to the company’s capital base. However, the stock is trading at a discount compared to its peers’ average historical valuations, reflecting market caution.
Built for the long haul! Consecutive quarters of strong growth landed this Small Cap from Chemicals on our Reliable Performers list. Sustainable gains are clearly ahead!
- - Long-term growth stock
- - Multi-quarter performance
- - Sustainable gains ahead
Financial Performance and Profitability Concerns
Recent quarterly results for Piramal Pharma reveal challenges in profitability. The Profit Before Tax excluding other income (PBT LESS OI) for the quarter stood at a loss of Rs.111.78 crore, representing a decline of 340.0% compared to the previous four-quarter average. Similarly, the Profit After Tax (PAT) recorded a loss of Rs.99.22 crore, down by 613.2% relative to the same benchmark.
Net sales for the quarter were Rs.2,043.72 crore, showing a reduction of 10.5% against the previous four-quarter average. These figures highlight a contraction in both top-line and bottom-line performance in the near term.
Over the last five years, the company’s net sales have grown at an annual rate of 9.15%, indicating moderate long-term growth. However, the average Return on Equity (ROE) is reported at 0.32%, signalling limited profitability generated per unit of shareholders’ funds.
Debt and Capital Structure
A notable factor influencing the stock’s performance is the company’s debt servicing capacity. The Debt to EBITDA ratio stands at 3.83 times, reflecting a relatively high leverage level. This ratio suggests that the company’s earnings before interest, taxes, depreciation, and amortisation may be under pressure to cover debt obligations efficiently.
Despite these concerns, institutional investors hold a significant stake in Piramal Pharma, with 45.17% of shares held by such entities. This level of institutional ownership indicates that investors with substantial resources continue to maintain positions in the company.
Piramal Pharma or something better? Our SwitchER feature analyzes this small-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Comparative Performance and Sector Context
When compared to the broader BSE500 index, Piramal Pharma’s stock has underperformed over multiple time frames, including the last three years, one year, and three months. This underperformance is notable given the Pharmaceuticals & Biotechnology sector’s overall resilience and the Sensex’s proximity to its 52-week high.
Operating profit has shown a compound annual growth rate of 23.29% over the long term, indicating some strength in core business operations despite recent setbacks. This growth rate contrasts with the decline in profits over the past year, which have fallen by 158.7%, underscoring volatility in earnings.
Summary of Key Metrics
To summarise, Piramal Pharma’s stock has reached Rs.170.15, its lowest level in 52 weeks, following a six-day losing streak and a year-long return of -34.28%. The company’s financial indicators reveal a high debt burden relative to earnings, subdued profitability, and a recent contraction in sales and profits. While the sector and broader market indices maintain more positive trajectories, the stock’s valuation remains discounted relative to peers.
Investors and market participants will continue to monitor these developments as the company navigates its current financial landscape.
Only for Rs. 14,999 - Get Access to 2 Years + 6 Months of All Premium Features on MarketsMojo. As low as ₹500/month! Claim 83% OFF →
